New drug cocktail aims to fight advanced uterine cancer
NCT ID NCT05077215
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding the drug EG-007 to a standard combination of lenvatinib and pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 participants will be randomly assigned to receive either the three-drug combo or the standard two-drug combo. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EG-007 (a repurposed drug) plus lenvatinib and pembrolizumab
- What this could lead to
- If successful, this could provide a new treatment option that slows cancer growth and improves survival for people with advanced endometrial cancer.
- What could go wrong
- This is an early-stage Phase 3 trial that hasn't started recruiting yet. Adding EG-007 may not improve outcomes and could increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
- New antibody drug targets Hard-to-Treat cancers in early trial
- New hope for advanced endometrial cancer: immunotherapy combo under study
- New drug combo shows promise for tough gynecological cancers
- New combo therapy shows promise for advanced uterine cancer
- Immune cell combo shows promise against tough gynecologic cancers